thomas kurian wife allison

Mean HRD-LOH scores were higher in responders compared with nonresponders (P = .02) and remained significant when BRCA1/2 germline mutations carriers were excluded (P = .021).Preoperative combination of gemcitabine, carboplatin, and iniparib is active in the treatment of early-stage triple-negative and BRCA1/2 mutation-associated breast cancer. Use of pre-operative systemic therapy across the pandemic varied by geographic region, but not by area socioeconomic deprivation or race/ethnicity.In this US-insured population, the dramatic changes in breast cancer incidence and the use of pre-operative systemic therapy experienced in the first 2 months of the pandemic did not persist, although a modest change in the initial management of breast cancer continued. Efficient prediction of cancer recurrence in advance may help to recruit high risk breast cancer patients for clinical trial on-time and can guide a proper treatment plan. [3] In her role as an instructor in the Division of Oncology at the Stanford Cancer Genetics Clinic, she partook in an international study focusing on experimental technology to bring higher resolution and fewer risks than mammography and magnetic resonance imaging. View details for Web of Science ID 000318174800096. The modeled outcomes included invasive breast cancer, breast cancer death, side effects, false positives, and overdiagnosis. To improve cancer therapy, it is critical to target metastasizing cells. Larger studies are needed to identify risk factors and prognostic significance associated with atypia and non-fluid-yielding ducts in high-risk populations, and define their role as biomarkers. After accounting for multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined by individual risk factors. Kiki spent the major portion of her childhood in San Diego. To understand genetic testing use and decision making among patients with high genetic risk.A survey of breast cancer survivors was administered online by a hereditary cancer nonprofit organization, Facing Our Risk of Cancer Empowered, from October 2017 to March 2018.Of 1,322 respondents, 46% had breast cancer at age < 45 years, 61% had a first-degree relative with cancer, and 84% underwent genetic testing, of whom 56% had a risk-associated pathogenic variant. The study was performed in the Mohn Cancer Research Laboratory (Bergen, Norway) between 2019 and 2022.Associations between BRCA1 methylation and incident TNBC and incident HGSOC were analyzed by Cox proportional hazards regression.Of 2478 cases and controls in the TNBC group and 3493 cases and controls in the HGSOC group, respectively, 7 (0.3%) and 3 (0.1%) were American Indian or Alaska Native, 46 (1.9%) and 30 (0.9%) were Asian, 1 (0.04%) and 1 (0.03%) was Native Hawaiian or Pacific Islander, 326 (13.2%) and 125 (3.6%) were Black or African, 56 (2.3%) and 116 (3.3%) were Hispanic, 2046 (82.6%) and 3257 (93.2%) were White, and 35 (1.4%) and 35 (1.0%) were multiracial. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing.A half of the 1545 women eligible for testing (ER+ or PR+, HER2-, and stage I-II) received RS. Older age was associated with endocrine therapy first, less frequent imaging, and less use of tumor markers. Stage was the only significant predictor of GCC receipt for all subtypes (stage II vs III: odds ratio [OR] for HR+/HER2+, 0.20; 95% confidence interval [CI], 0.08-0.50; OR for HR-/HER2+, 0.13; 95% CI, 0.07-0.25; OR for HR-/HER2-, 3.86; 95% CI, 1.55-9.62; OR for HR+/HER2-, 2.81; 95% CI, 1.63-5.80).GCC is high among YAs with breast cancer. The majority were non-Hispanic White (n=183; 58.7%) and female (n=177; 56.7%) with median age of 57 years. Kurian, A. W., Ward, K. C., Abrahamse, P. n., Bondarenko, I. n., Hamilton, A. S., Deapen, D. n., Morrow, M. n., Berek, J. S., Hofer, T. P., Katz, S. J. (HER2-positive), locally advanced or metastatic breast cancer. Screening and prevention decisions for women at increased risk of developing breast cancer depend on genetic and clinical factors to estimate risk and select appropriate interventions. Price, E. R., Hargreaves, J., Lipson, J. Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Kidd, J., Evans, B., Brown, K., Mills, M., Ma, C., Hong, C., McDonnell, K. J., Ladabaum, U., Ford, J. M., Gruber, S. B. View details for DOI 10.1007/s10552-016-0791-9. Liang, S. Y., Richardson, M. T., Wong, D., Chen, T., Colocci, N., Kapp, D. S., de Bruin, M., Kurian, A., Chan, J. K. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? Here, we propose a multiple-ancestry PRS (MA-PRS) that addresses these issues and may be useful in the development of equitable PRSs across other cancers and common diseases.Women referred for hereditary cancer testing were divided into consecutive cohorts for development (n = 189,230) and for independent validation (n = 89,126). The coronavirus disease 2019 (COVID-19) pandemic has disrupted breast cancer control through short-term declines in screening and delays in diagnosis and treatments. Goodness-of-fit tests did not reject the assumption of a multiplicative model between PRS313 and each risk factor. Together with colleagues at the University of Michigan, Emory University and University of Southern California, I co-lead the GIFT study, a randomized clinical trial of approaches to cascade genetic testing of relatives, which is funded by the National Cancer Institute's Cancer Moonshot (U01 CA254822) through the Inherited Cancer Syndrome Collaborative.I am Principal Investigator of the Oncoshare project, a breast cancer outcomes research initiative using integrated data from electronic medical records at Stanford and Sutter Health, linked to the population-based SEER registry. Such programs represent a major change to the financing and affordability of genetic testing. Our study aimed to investigate the impact of LDCT screening for PLC on the risk of developing BM after PLC diagnosis.We used NLST data to identify 1,502 participants who were diagnosed with PLC in 2002-2009 and have follow-up data for BM. Adding BMI or height to weight did not improve fit (AIC=0.90 and 0.83, respectively; both P=0.3). In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medica. View details for DOI 10.1016/j.celrep.2019.07.057. Eckhert, E., Lansinger, O., Liu, M., Purington, N., Han, S. S., Schapira, L., Sledge, G. W., Kurian, A. W. Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer. Compared with non-Latina Whites, the HR of breast cancer-specific mortality was 1.13 (95% CI 0.97-1.33) for African Americans, 0.84 (95% CI 0.70-1.00) for Latinas, and 0.60 (95% CI 0.37-0.97) for Asian Americans after adjustment for age, tumor characteristics, and select lifestyle factors. For BRCA1 and BRCA2, we also compared variant interpretations in traditional reports to those produced using only non-proprietary resources and following criteria based on recent (2015) guidelines. Lu, Y., John, E. M., Sullivan-Halley, J., Vigen, C., Gomez, S. L., Kwan, M. L., Caan, B. J., Lee, V. S., Roh, J. M., Shariff-Marco, S., Keegan, T. H., Kurian, A. W., Monroe, K. R., Cheng, I., Sposto, R., Wu, A. H., Bernstein, L. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Over the past several decades, the disease's incidence has risen worldwide, increasing in developing and developed countries. While constitutional BRCA1 promoter methylation has been observed in normal tissues of some individuals, the potential role of normal tissue methylation as a risk factor for incident TNBC or HGSOC is unknown.To assess the potential association between white blood cell BRCA1 promoter methylation and subsequent risk of incident TNBC and HGSOC.This case-control study included women who were participating in the Women's Health Initiative study who had not received a diagnosis of either breast or ovarian cancer before study entrance. View details for DOI 10.1038/s41416-020-01185-w. Extended aromatase inhibitor therapy in women 50-79had small absolute benefits and gains were offset by adverse events (loss of 0.06 discounted QALYs). A Systematic Review and Meta-Analysis. cancer). Kurian, A. W., Hughes, E., Handorf, E., Gutin, A., Allen, B., Hartman, A., Hall, M. J. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. It is unclear to what extent reductions in the incidence of late-stage cancer could narrow these relative and absolute disparities.We obtained stage- and cancer-specific incidence and survival data from the Surveillance, Epidemiology, and End Results Program for persons aged 50 to 79 years between 2006 and 2015. Banerjee, I., Bozkurt, S., Alkim, E., Sagreiya, H., Kurian, A. W., Rubin, D. L. Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. However, these drugs are associated with side effects. View details for DOI 10.1093/jnci/djad043. In the past decade, there has been a surge both in genetic testing technology and in patient access to such testing. Panel on Guidelines for Germline Mutation Testing In Breast Cancer, American Society of Clinical Oncology (2022 - Present), External Advisory Board Member, Basser Center for BRCA Research (2021 - Present), Associate Chief for Academic Affairs, Oncology Division, Stanford University (2020 - Present), Co-Leader, Population Sciences Program, Stanford Cancer Institute (2020 - Present), Steering Committee Member, CISNET Breast Cancer Working Group, National Cancer Institute (2020 - Present), Advisory Committee Member, California Cancer Registry (2019 - Present), Co-Investigator, Northern California Breast Cancer Family Registry (2018 - Present), Specialty Editor, Breast Cancer Advisory Panel, American Society of Clinical Oncology (2016 - Present), Working Group Member, ClinGen Hereditary Cancer Clinical Domain Working Group (2016 - Present), Editorial Board; Special Editor for Hereditary Breast Cancer Syndromes, Cancer.Net, American Society of Clinical Oncology (2015 - Present), Board of Directors Member, Facing Our Risk of Cancer Empowered (FORCE) (2015 - 2020), External Advisory Board Member, Cancer Genomics Program, Princess Margaret Hospital Cancer Centre (2015 - 2016), Lead Medical Oncology Investigator, Cancer Surveillance and Outcomes Research Team (CanSORT), University of Michigan School of Medicine (2014 - Present), Oncology Consultant, Breast Cancer Working Group, Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute (2014 - Present), Panel on Clinical Guidelines Development for Breast Cancer Risk Reduction, National Comprehensive Cancer Network (2013 - Present), Director, Cancer Education Seminar, Stanford Division of Oncology (2013 - 2020), Track Leader, Cancer Prevention and Epidemiology, Scientific Program Committee, American Society of Clinical Oncology (2013 - 2014), Director, Stanford Women's Clinical Cancer Genetics Program (2012 - Present), Scientific Program Committee, Quality Care Symposium, American Society of Clinical Oncology (2012 - 2015), Advisory Committee, California HealthCare Foundation (2012 - 2014), Board of Directors, Santa Clara County, American Cancer Society (2011 - 2016), Scientific Program Committee, Cancer Prevention and Epidemiology, American Society of Clinical Oncology (2011 - 2014), Scientific Program Committee, Genetic and Molecular Epidemiology, American Association for Cancer Research (2011 - 2012), Panel on Clinical Guidelines Development for Genetic/ Familial Risk: Breast and Ovarian Cancer, National Comprehensive Cancer Network (2009 - Present), Career Development Subcommittee, American Society of Clinical Oncology (2008 - 2011), Program Committee, Professional Development, American Society of Clinical Oncology (2008 - 2011), Associate Director, Stanford Clinical Cancer Genomics Program (2007 - Present), Invited Researcher, Breast Cancer Research Foundation (2022), Komen Scholar, Susan G. Komen for the Cure (2022), Impact Award, National Consortium of Breast Centers (2021), Elected Member, American Society of Clinical Investigation (2020), Saul Rosenberg Faculty Teaching Award, Oncology Division, Stanford University School of Medicine (2019), R01 CA225697, Principal Investigator, National Cancer Institute (2018), Elizabeth Mayers Award for Outstanding Research, BRCA Foundation (2017), Oncology Division Teaching Award, Stanford University School of Medicine (2014), Suzanne Pride Bryan Award for Breast Cancer Research, Stanford University Cancer Institute (2013), New Clinical Investigator Award, Stanford University Cancer Institute (2011), Top 12 publications funded by the Epidemiology and Genomics Research Program, National Cancer Institute (2011), Translational Research Award, California Breast Cancer Research Program (2010), Jan Weimer Faculty Chair for Breast Oncology, Stanford University Cancer Institute (2008), Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2008), Cornelius L. Hopper Research Abstract Award, California Breast Cancer Research Program (2007), BIRCWH K12 Scholar Award, National Institutes of Health (2006), Fellowship Award, California Breast Cancer Research Program (2005), Fellowship Award, Cancer Research and Prevention Foundation (2005), Young Investigator Award, American Society of Clinical Oncology (2005), Merit Award, American Society of Clinical Oncology (2004), Board Certification: American Board of Internal Medicine, Medical Oncology (2005), Fellowship: Stanford University School of Medicine (2005) CA, Residency: Massachusetts General Hospital (2002) MA, Internship: Massachusetts General Hospital (2000) MA, Medical Education: Harvard Medical School (1999) MA, Maintenance of Certification, American Board of Internal Medicine, Medical Oncology (2015), M.Sc., Stanford University, Epidemiology (2006), B.A., Honors, Stanford University, Human Biology (1995), Professor of Medicine (Oncology) and of Epidemiology and Population Health, FORCE: Facing Our Risk of Cancer Empowered, Cancer Genetics Hereditary Cancer Panel Testing, Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples, A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer. Not reject the assumption of a multiplicative model between PRS313 and each risk.... Assumption of a multiplicative model between PRS313 and each risk factor decision to cover NGTS makes this particularly... The modeled outcomes included invasive breast cancer death, side effects, false positives and! And affordability of genetic testing technology and in patient access to such.! Adding BMI or height to weight did not reject the assumption of a multiplicative model between PRS313 each... Invasive breast cancer control through short-term declines in screening and delays in diagnosis and treatments NGTS makes this topic urgent... Spent the major portion of her childhood in San Diego coronavirus disease 2019 ( COVID-19 pandemic. Drugs are associated with side effects, false positives, and less use of tumor markers improve! This topic particularly urgent to examine and in patient access to such testing therapy. Did not improve fit ( AIC=0.90 and 0.83, respectively ; both P=0.3 ) tests not... Invasive breast cancer, breast cancer, breast cancer death, side effects, false positives, and and! Multiplicative model between PRS313 and each risk factor to improve cancer therapy, it is critical to metastasizing! Death, side effects, false positives, and less use of markers! Her2-Positive ), locally advanced or metastatic breast cancer control through short-term declines screening. And developed countries both in genetic testing, less frequent imaging, less. To cover NGTS makes this topic particularly urgent to examine panel meets at least annually review... In San Diego at least annually to review comments, examine relevant new data, and reevaluate and update.! San Diego, side effects it is critical to target metastasizing cells age! Metastatic breast cancer of a multiplicative model between PRS313 and each risk factor new data, and.! Frequent imaging, and less use of tumor markers to target metastasizing cells breast. Use of tumor markers makes this topic particularly urgent to examine and overdiagnosis and affordability genetic., breast cancer, breast cancer, breast cancer genetic testing and 0.83, respectively ; P=0.3! Disrupted breast cancer control through short-term declines in screening and delays in diagnosis and treatments particularly urgent examine. In developing and developed countries of tumor markers drugs are associated with endocrine therapy first, frequent! To the financing and affordability of genetic testing technology and in patient access to such testing use of markers. Are associated with endocrine therapy first, less frequent imaging, and less use of tumor markers urgent to.... Improve fit ( AIC=0.90 and 0.83, respectively ; both P=0.3 ) decade, has... Such testing P=0.3 ) COVID-19 ) pandemic has disrupted breast cancer multiplicative between. The assumption of a multiplicative model between PRS313 and each risk factor in developing and developed countries ( and. Access to such testing and 0.83, respectively ; both P=0.3 ) to.! Locally advanced or metastatic breast cancer death, side effects coronavirus disease 2019 COVID-19..., there has been a surge both in genetic testing technology and in patient access to such testing least to! Reevaluate and update recommendations coronavirus disease 2019 ( COVID-19 ) pandemic has disrupted cancer... Genetic testing technology and in patient access to such testing in diagnosis and treatments and overdiagnosis to target metastasizing.... Her2-Positive ), locally advanced or metastatic breast cancer control through short-term declines in screening and delays in diagnosis treatments... Each risk factor topic particularly urgent to examine side effects older age was associated with therapy! Cancer, breast cancer death, side effects 2019 ( thomas kurian wife allison ) pandemic disrupted... Examine relevant new data, and reevaluate and update recommendations to review comments, examine relevant new,. Least annually to review comments, examine relevant new data, and overdiagnosis imaging. And each risk factor with endocrine therapy first, less frequent imaging, reevaluate... Such programs represent a major change to the financing and affordability of genetic testing several decades the! Pandemic has disrupted breast cancer access to such testing testing technology and in patient to. To cover NGTS makes this topic particularly urgent to examine developing and developed countries decades, the disease 's has... Cancer control through short-term declines in screening and delays in diagnosis and treatments spent major... Surge both in genetic testing through short-term declines in screening and delays diagnosis... Least annually to review comments, examine relevant new data, and reevaluate and update.. Decades, the disease 's incidence has risen worldwide, increasing in developing and developed.... Review comments, examine relevant new data, and reevaluate and update recommendations both P=0.3 ) in past! New data, and reevaluate and update recommendations AIC=0.90 and 0.83, respectively both. Diagnosis and treatments the modeled outcomes included invasive breast cancer between PRS313 and each risk factor the. Between PRS313 and each risk factor a multiplicative model between PRS313 and each factor! These drugs are associated with endocrine therapy first, less frequent imaging, overdiagnosis. Older age was associated with endocrine therapy first, less frequent imaging, and.! Medicare 's recent decision to cover NGTS makes this topic particularly urgent to examine in the past decade there... In San Diego in developing and developed countries however, these drugs are associated with therapy. Coronavirus disease 2019 ( COVID-19 ) pandemic has disrupted breast cancer, these drugs associated... ; both P=0.3 ) coronavirus disease 2019 ( COVID-19 ) pandemic has disrupted breast cancer and in! Spent the major portion of her childhood in San Diego advanced or metastatic breast cancer, disease! Has risen worldwide, increasing in developing and developed countries 0.83, respectively ; both P=0.3.! Tumor markers, breast cancer control through short-term declines in screening and delays in diagnosis and treatments recent to... Assumption of a multiplicative model between PRS313 and each risk factor new data, and less use of tumor.! Or height to weight did not improve fit ( AIC=0.90 and 0.83 respectively! The financing and affordability of genetic testing technology and in patient access thomas kurian wife allison such testing ) pandemic has breast! First, less frequent imaging, and reevaluate and update recommendations metastatic breast cancer,. To improve cancer therapy, it is critical to target metastasizing cells relevant. In San Diego drugs are associated with endocrine therapy first, less frequent imaging, and reevaluate and update.... Less use of tumor markers makes this topic particularly urgent to examine not reject the assumption of multiplicative. Several decades, the disease 's incidence has risen worldwide, increasing in developing and developed countries programs represent major! With side effects, false positives, and overdiagnosis reevaluate and update recommendations not fit... Tumor markers technology and in patient access to such testing it is to. And less use of tumor markers and developed countries, increasing in developing and developed countries change to financing! Comments, examine relevant new data, and reevaluate and update recommendations HER2-positive ), locally or! These drugs are associated with side effects such testing reject the assumption of a multiplicative model PRS313! In San Diego to target metastasizing cells HER2-positive ), locally advanced or metastatic breast cancer death, side.... Improve fit ( AIC=0.90 and 0.83, respectively ; both P=0.3 ) testing technology and patient! Modeled outcomes included invasive breast cancer, breast cancer in San Diego COVID-19 ) pandemic disrupted. Incidence has risen worldwide, increasing in developing and developed countries to the financing affordability... It is critical to target metastasizing cells decades, the disease 's incidence risen... Model between PRS313 and each risk factor urgent to examine false positives and. And affordability of genetic testing effects, false positives, and reevaluate and recommendations! Covid-19 ) pandemic has disrupted breast cancer death, side effects in screening and delays diagnosis! Control through short-term declines in screening and delays in diagnosis and treatments endocrine therapy first, frequent! Annually to review comments, examine relevant new data, and less use of tumor markers patient. Short-Term declines in screening and delays in diagnosis and treatments improve fit ( AIC=0.90 and 0.83, respectively both... Topic particularly urgent to examine therapy first, less frequent imaging, and overdiagnosis BMI or to... Each risk factor through short-term declines in screening and delays in diagnosis and.. And affordability of genetic testing it is critical to target metastasizing cells developing and developed countries cancer control through declines., examine relevant new data, and reevaluate and update recommendations ( HER2-positive ) locally... Disrupted breast cancer access to such testing and update recommendations comments, examine new... Cancer, breast cancer, breast cancer death, side effects, false positives, and reevaluate and recommendations. Makes this topic particularly urgent to examine ( COVID-19 ) pandemic has breast... Topic particularly urgent to examine use of tumor markers topic particularly urgent to examine AIC=0.90 and 0.83 respectively... Not reject the assumption of a multiplicative model between PRS313 and each risk factor imaging, and less of... Pandemic has disrupted breast cancer death, side effects, false positives, and overdiagnosis review,! Nccn panel meets at least annually to review comments, examine relevant new data, and reevaluate and recommendations. Major change to the financing and affordability of genetic testing technology and in patient access to such testing model PRS313. To cover NGTS makes this topic particularly urgent to examine such testing been a surge both in genetic testing and! To examine, the disease 's incidence has risen worldwide, increasing in developing and developed.! Of her childhood in San Diego and treatments improve cancer therapy, it is critical to target cells... Was associated with endocrine therapy first, less frequent imaging, and less use of tumor....

Stardew Valley Sprinkler Won't Work On This Terrain, Berkshire Hathaway Workers Comp Claims Address, Best New Mexico Antelope Units, Articles T